Captopril, spironolactone and carvedilol breast cancer

Comparative study of captopril, spinenolactone and carvedilol on endothelial function in women with breast cancer under chemotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017061034432N1

Enrollment

Registered

2017-08-14

Start date

2018-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention group: Captopril, 5.12 mg oral tablet, twice a day for three months

Spironolactone, 25 mg oral tablet, once a day for three months

Carvedilol, 125.3 mg oral tablet, twice a day for three months. Intervention 2: Control group: Placebo, 5.12 mg oral tablet, twice a day for three months

Placebo, 25 mg oral tablet, once a day for three months

Placebo, 125.3 mg oral tablet, twice a day for three months.

Treatment - Drugs

Intervention group: Captopril, 5.12 mg oral tablet, twice a day for three months

Carvedilol, 125.3 mg oral tablet, twice a day for three months

Control group: Placebo, 5.12 mg oral tablet, twice a day for three months

Placebo, 125.3 mg oral tablet, twice a day for three months

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Women with breast cancer chemotherapy candidate; aged 30-70 years; having sinus rhythm; having echocardiography for LVEF (equal to or greater than 50%) Exclusion criteria: LVEF Less than 50%; previous myocardial infarction or known coronary artery disease; significant valvulopathy or cardiomyopathy (GFR <30 mm / min / 1.73m2); patients treated with ACEI, beta blocker, or ARB; drug sensitivity to ACEI, beta blocker, ARB; (SBP <90 mmHg and HR <60 beat / min); patients who currently have an AF rhythm and need treatment with class I antiarrhythmic drugs; pregnancy; dissatisfaction with participation in the research project; death

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mean percent of flow-mediated vasodilatation (FMD) of Brachial artery. Timepoint: Before the chemotherapy, after the chemotherapy. Method of measurement: high resolution ultrasound.;Diastolic functional index. Timepoint: Before the chemotherapy, after the chemotherapy. Method of measurement: Echocardiography.;Mean percent of left ventricular ejection fraction (LVEF). Timepoint: Before the chemotherapy, after the chemotherapy. Method of measurement: Echocardiography.	—

Measure

Time frame

Mean percent of flow-mediated vasodilatation (FMD) of Brachial artery. Timepoint: Before the chemotherapy, after the chemotherapy. Method of measurement: high resolution ultrasound.;Diastolic functional index. Timepoint: Before the chemotherapy, after the chemotherapy. Method of measurement: Echocardiography.;Mean percent of left ventricular ejection fraction (LVEF). Timepoint: Before the chemotherapy, after the chemotherapy. Method of measurement: Echocardiography.

—

Secondary

Measure	Time frame
Blood urea nitrogen. Timepoint: Before starting the medication, two weeks after starting the medications, monthly. Method of measurement: Blood test.;Creatinine. Timepoint: Before starting the medication, two weeks after starting the medications, monthly. Method of measurement: Blood test.;Sodium. Timepoint: Before starting the medication, two weeks after starting the medications, monthly. Method of measurement: Blood test.;Potassium. Timepoint: Before starting the medication, two weeks after starting the medications, monthly. Method of measurement: Blood test.	—

Measure

Time frame

Blood urea nitrogen. Timepoint: Before starting the medication, two weeks after starting the medications, monthly. Method of measurement: Blood test.;Creatinine. Timepoint: Before starting the medication, two weeks after starting the medications, monthly. Method of measurement: Blood test.;Sodium. Timepoint: Before starting the medication, two weeks after starting the medications, monthly. Method of measurement: Blood test.;Potassium. Timepoint: Before starting the medication, two weeks after starting the medications, monthly. Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Faranak Tayebi

Vice-chancellor of research, Isfahan University of Medical Sciences

tayebifaranak@gmail.com; mohammad_hashemi@med.mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026